Recursion, one of the most buzzed-about startups using machine learning to speed up drug discovery trials, said Wednesday it raised $239 million in Series D led by pharmaceutical maker Bayer. Recursion’s pre-investment valuation was a hair below $1 billion, according to a person with knowledge of the matter. Separately, Bayer is paying the seven-year-old Salt Lake City-based company $30 million...